Endologix Appoints Tim A. Benner as Chief Commercial Officer

Mr. Benner brings to Endologix over a decade of commercial, sales and marketing, strategy, and business development experience in the medical device industry. Most recently, he served as General Manager and Division Vice President of the U.S. Region for Abbott’s Structural Heart business. While at Abbott, he directed the U.S. commercial organization with responsibility for sales, marketing, and the P&L across the TMVr (MitraClip), Structural Interventions (Amplatzer), Surgical Valves, and TAVR franchises. Prior to that, he spent nine years at Edwards Lifesciences in positions of increasing responsibility in Strategy, Business Development, Global Marketing, Commercial Operations, and Market Development. Mr. Benner also served on Edwards’ Senior Leadership Team (SLT).

John Onopchenko, Chief Executive Officer of Endologix, commented, “We are thrilled to welcome Tim to our executive team. He has demonstrated a strong track-record of achievement in the medical device industry, implementing a number of successful commercial strategies across a variety of unique product families and markets. We are excited to have Tim on board to spearhead our commercial strategy and put AFX2, Ovation, Alto, Nellix, and ChEVAS in the hands of physicians around the globe.”

Mr. Benner added, “I’m excited to join the Endologix team, and I strongly believe that we can leverage the Company’s unique and innovative portfolio to capitalize on the many opportunities in the EVAR market. I look forward to working with the Endologix team to drive the procedural growth that will generate outcomes data and bring our life-saving technology to patients in need.”

Mr. Benner earned his Master of Business Administration from the University of California, Irvine, conducted graduate-level MS-BA coursework at the University of Southern California, and completed his Bachelor of Science in Business Administration from California State University, Long Beach.

About Endologix, Inc.
Endologix, Inc. develops, manufactures, markets and sells innovative medical devices for the treatment of aortic disorders. The Company’s products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms (“AAA”). AAA occurs when a portion of the abdominal aorta bulges into an aneurysm because of a weakening of the vessel wall, which may result in life threatening internal bleeding upon rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it among the leading causes of death in the United States. For more information, visit www.endologix.com.

Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements used in this press release include, but are not limited to, statements regarding the anticipated commencement (and commensurate benefits) of Mr. Benner’s employment with Endologix (including anticipated strengthening and extension of Endologix’s customer partnerships and commercial execution, and securing increased market share and procedural growth), the accuracy of which are necessarily subject to risks and uncertainties that may cause Endologix’s actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ materially and adversely from anticipated results include continued market acceptance, hiring, integration and retention of Mr. Benner, risks regarding Quality systems operations and outcome of third party audits of such systems, endorsement and use of Endologix’s products, risks associated with the manufacturing of Endologix’s products, the success of clinical trials relating to Endologix’s products, product research and development efforts, uncertainty in the process of obtaining and maintaining U.S. FDA and other regulatory approvals for Endologix’s products, Endologix’s ability to access equity and debt capital on acceptable terms, Endologix’s ability to enter into or maintain existing financing arrangements on acceptable terms, risks associated with international operations, including currency exchange rate fluctuations, Endologix’s ability to protect its intellectual property rights and proprietary technologies, and other economic, business, competitive and regulatory factors. Undue reliance should not be placed upon the forward-looking statements contained in this press release, which speak only as of the date of this press release. Endologix undertakes no obligation to update any forward-looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2019, for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005789/en/